MedTrace Logo

Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors

NCT00004922 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-19

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have advanced neuroendocrine tumors.

Conditions

  • Carcinoma of Unknown Primary
  • Neuroendocrine Carcinoma
  • Neuroendocrine Carcinoma of the Skin

Interventions

DRUG

irinotecan hydrochloride

Sponsors & Collaborators

Principal Investigators

  • Sunil Sharma, MD · Memorial Sloan Kettering Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-06-30
Primary Completion
2002-06-30
Completion
2002-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004922 on ClinicalTrials.gov